Skip to main content
Clinical Trials/IRCT20190618043934N1
IRCT20190618043934N1CompletedPhase 3

Study of the Effect of Coenzyme Q10 supplementation on inflammatory markers(high-sensitivity C-reactive protein, interleukin-6, and oxidative stress and increases antioxidant enzyme activity) in patients with COPD

Birjand University of Medical Sciences0 sites90 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Completed
Enrollment
90

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • At least 18 years of age, no nutritional and pharmaceutical supplementation, and informed consent.

Exclusion Criteria

  • diagnosis of mellitus diabetes, PTE, CKD, CAD and bacterial pneumonia or taking any complementary medicines.Also diagnosis of COPD with current treatment of antioxidant medicine and supplements or any medicine that affects antioxidant storage and mitocondrial system.

Investigators

Similar Trials